Quince Therapeutics shares surge 10.07% intraday after hiring LifeSci Capital as exclusive financial advisor to restructure and evaluate strategic options including partnerships, mergers, or acquisitions.

martes, 24 de febrero de 2026, 10:42 am ET1 min de lectura
QNCX--
Quince Therapeutics surged 10.07% intraday as the company announced hiring LifeSci Capital as an exclusive financial advisor to assist with restructuring and evaluating strategic alternatives, including potential partnerships, joint ventures, mergers, or acquisitions, aiming to maximize shareholder value. The company specializes in leveraging patients' own biology to treat rare diseases, with its core product EryDex developed using the proprietary AIDE technology platform.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios